Modalis Therapeutics Corp
TSE:4883
Modalis Therapeutics Corp
Operating Expenses
Modalis Therapeutics Corp
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Modalis Therapeutics Corp
TSE:4883
|
Operating Expenses
-¥2.4B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Operating Expenses
-¥17.3B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-36%
|
|
PeptiDream Inc
TSE:4587
|
Operating Expenses
-¥10.4B
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
TSE:4974
|
Operating Expenses
-¥23.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Operating Expenses
-¥46B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-49%
|
|
S
|
StemRIM Inc
TSE:4599
|
Operating Expenses
-¥2.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
See Also
What is Modalis Therapeutics Corp's Operating Expenses?
Operating Expenses
-2.4B
JPY
Based on the financial report for Dec 31, 2023, Modalis Therapeutics Corp's Operating Expenses amounts to -2.4B JPY.
What is Modalis Therapeutics Corp's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-53%
Over the last year, the Operating Expenses growth was -13%. The average annual Operating Expenses growth rates for Modalis Therapeutics Corp have been -47% over the past three years , -53% over the past five years .